List view / Grid view
24 February 2015 | By Prexton Therapeutics
Swiss based startup attracts venture funding from leading European VC firms to address Parkinson’s disease and other CNS conditions...
23 February 2015 | By Celltrion Healthcare
Cost savings could help improve patient access to life-changing treatment...
23 February 2015 | By Eyevensys
Eyevensys, an innovative ophthalmic therapy company, announced the appointment Dr. Violaine Desort-Hénin as Clinical Director...
19 February 2015 | By The Institute of Cancer Research
Single-letter genetic variations within parts of the genome once dismissed as ‘junk DNA’ can increase cancer risk through wormhole-like effects on far-off genes, new research shows...
19 February 2015 | By Roche
The Institute’s mission is to consolidate and expand R&D partnerships in France with Centres of Excellence in translational Medicine...
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
13 February 2015 | By Effimune
Two major scientific articles validate Effimune’s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system...
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
9 February 2015 | By SensiQ Technologies/Inventiva
Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation...
9 February 2015 | By Cell Therapy Ltd
UK biotech company Cell Therapy Limited has raised over £691,000 on Crowdcube to fund its breakthrough stem cell medicine, Heartcel™, which regenerates heart muscle to treat heart failure...
6 February 2015 | By Genticel
Genticel announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 – 7...
5 February 2015 | By The Institute of Cancer Research
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown...
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
5 February 2015 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the appointment of Dr. Christian Schetter as CEO...
5 February 2015 | By The Institute of Cancer Research
A worldwide study of the DNA of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer...
